1. Home
  2. IMUX vs SFWL Comparison

IMUX vs SFWL Comparison

Compare IMUX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • SFWL
  • Stock Information
  • Founded
  • IMUX 2016
  • SFWL 2001
  • Country
  • IMUX United States
  • SFWL China
  • Employees
  • IMUX N/A
  • SFWL N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • SFWL Trucking Freight/Courier Services
  • Sector
  • IMUX Health Care
  • SFWL Industrials
  • Exchange
  • IMUX Nasdaq
  • SFWL Nasdaq
  • Market Cap
  • IMUX 86.3M
  • SFWL 80.8M
  • IPO Year
  • IMUX N/A
  • SFWL 2023
  • Fundamental
  • Price
  • IMUX $0.98
  • SFWL $1.02
  • Analyst Decision
  • IMUX Strong Buy
  • SFWL
  • Analyst Count
  • IMUX 6
  • SFWL 0
  • Target Price
  • IMUX $12.67
  • SFWL N/A
  • AVG Volume (30 Days)
  • IMUX 1.0M
  • SFWL 20.5K
  • Earning Date
  • IMUX 02-20-2025
  • SFWL 03-27-2025
  • Dividend Yield
  • IMUX N/A
  • SFWL N/A
  • EPS Growth
  • IMUX N/A
  • SFWL N/A
  • EPS
  • IMUX N/A
  • SFWL 0.11
  • Revenue
  • IMUX N/A
  • SFWL $446,281,000.00
  • Revenue This Year
  • IMUX N/A
  • SFWL N/A
  • Revenue Next Year
  • IMUX N/A
  • SFWL N/A
  • P/E Ratio
  • IMUX N/A
  • SFWL $9.47
  • Revenue Growth
  • IMUX N/A
  • SFWL 14.80
  • 52 Week Low
  • IMUX $0.92
  • SFWL $0.81
  • 52 Week High
  • IMUX $2.11
  • SFWL $2.23
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 44.34
  • SFWL 46.64
  • Support Level
  • IMUX $0.94
  • SFWL $0.98
  • Resistance Level
  • IMUX $1.02
  • SFWL $1.08
  • Average True Range (ATR)
  • IMUX 0.06
  • SFWL 0.05
  • MACD
  • IMUX 0.00
  • SFWL 0.00
  • Stochastic Oscillator
  • IMUX 44.96
  • SFWL 48.00

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About SFWL Shengfeng Development Limited

Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.

Share on Social Networks: